{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,8]],"date-time":"2026-07-08T02:30:05Z","timestamp":1783477805784,"version":"3.55.0"},"reference-count":29,"publisher":"The Endocrine Society","issue":"10","license":[{"start":{"date-parts":[[2020,8,1]],"date-time":"2020-08-01T00:00:00Z","timestamp":1596240000000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"name":"Shire Human Genetic Therapies, Inc."}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2020,10,1]]},"abstract":"<jats:title>Abstract<\/jats:title>\n               <jats:sec>\n                  <jats:title>Context<\/jats:title>\n                  <jats:p>Chronic hypoparathyroidism (HypoPT) is conventionally managed with oral calcium and active vitamin D. Recombinant human parathyroid hormone (1\u201384) (rhPTH[1\u201384]) is a therapy targeting the pathophysiology of HypoPT by replacing parathyroid hormone.<\/jats:p>\n               <\/jats:sec>\n               <jats:sec>\n                  <jats:title>Objective<\/jats:title>\n                  <jats:p>To compare changes in the estimated glomerular filtration rate (eGFR) in patients with chronic HypoPT receiving or not receiving rhPTH(1\u201384) during a 5-year period.<\/jats:p>\n               <\/jats:sec>\n               <jats:sec>\n                  <jats:title>Design\/Setting<\/jats:title>\n                  <jats:p>A retrospective analysis of patients with chronic HypoPT treated with or without rhPTH(1\u201384).<\/jats:p>\n               <\/jats:sec>\n               <jats:sec>\n                  <jats:title>Patients<\/jats:title>\n                  <jats:p>Sixty-nine patients with chronic HypoPT from 4 open-label, long-term trials (NCT00732615, NCT01268098, NCT01297309, and NCT02910466) composed the rhPTH(1\u201384) cohort and 53 patients with chronic HypoPT not receiving rhPTH(1\u201384) from the Geisinger Healthcare Database (01\/2004\u201306\/2016) composed the historical control cohort.<\/jats:p>\n               <\/jats:sec>\n               <jats:sec>\n                  <jats:title>Interventions<\/jats:title>\n                  <jats:p>The rhPTH(1\u201384) cohort (N = 69) received rhPTH(1\u201384) therapy; the historical control cohort (N = 53) did not receive rhPTH(1\u201384).<\/jats:p>\n               <\/jats:sec>\n               <jats:sec>\n                  <jats:title>Main Outcome Measures<\/jats:title>\n                  <jats:p>Changes in eGFR from baseline during a 5-year follow-up were examined in multivariate regression analyses.<\/jats:p>\n               <\/jats:sec>\n               <jats:sec>\n                  <jats:title>Results<\/jats:title>\n                  <jats:p>At baseline, demographic characteristics and eGFR were similar between cohorts, though the proportions with diabetes and cardiac disorders were lower in the rhPTH(1\u201384) cohort. At the end of follow-up, mean eGFR increased by 2.8 mL\/min\/1.73 m2 in the rhPTH(1\u201384) cohort, while mean eGFR fell by 8.0 mL\/min\/1.73 m2 in the control cohort. In the adjusted model, the difference in the annual eGFR change between the rhPTH(1\u201384) cohort and the control cohort was 1.7 mL\/min\/1.73 m2 per year (P = 0.009).<\/jats:p>\n               <\/jats:sec>\n               <jats:sec>\n                  <jats:title>Conclusions<\/jats:title>\n                  <jats:p>Estimated glomerular filtration rate was preserved for over 5 years among patients with chronic HypoPT receiving rhPTH(1\u201384) treatment, contrasting with an eGFR decline among those not receiving rhPTH(1\u201384).<\/jats:p>\n               <\/jats:sec>","DOI":"10.1210\/clinem\/dgaa490","type":"journal-article","created":{"date-parts":[[2020,8,1]],"date-time":"2020-08-01T12:47:12Z","timestamp":1596286032000},"page":"e3557-e3565","source":"Crossref","is-referenced-by-count":27,"title":["Five-year Estimated Glomerular Filtration Rate in Patients With Hypoparathyroidism Treated With and Without rhPTH(1\u201384)"],"prefix":"10.1210","volume":"105","author":[{"ORCID":"https:\/\/orcid.org\/0000-0003-3428-9570","authenticated-orcid":false,"given":"Kristina S","family":"Chen","sequence":"first","affiliation":[{"name":"Shire Human Genetic Therapies, Inc., Cambridge, Massachusetts (a Takeda company)"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Elvira O","family":"Gosmanova","sequence":"additional","affiliation":[{"name":"Division of Nephrology, Albany Medical College and Nephrology Section, Stratton VA Medical Center, Albany, New York"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Gary C","family":"Curhan","sequence":"additional","affiliation":[{"name":"Renal Division, Brigham and Women\u2019s Hospital, Harvard Medical School, Boston, Massachusetts"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Markus","family":"Ketteler","sequence":"additional","affiliation":[{"name":"Department of General Internal Medicine and Nephrology, Robert-Bosch-Krankenhaus, Stuttgart, Germany"},{"name":"Department of Medicine Program, University of Split School of Medicine, Split, Croatia"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mishaela","family":"Rubin","sequence":"additional","affiliation":[{"name":"Columbia University College of Physicians and Surgeons, New York, New York"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Elyse","family":"Swallow","sequence":"additional","affiliation":[{"name":"Analysis Group Inc., Boston, Massachusetts"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jing","family":"Zhao","sequence":"additional","affiliation":[{"name":"Analysis Group Inc., Boston, Massachusetts"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jessie","family":"Wang","sequence":"additional","affiliation":[{"name":"Analysis Group Inc., Boston, Massachusetts"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nicole","family":"Sherry","sequence":"additional","affiliation":[{"name":"Shire Human Genetic Therapies, Inc., Cambridge, Massachusetts (a Takeda company)"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Alan","family":"Krasner","sequence":"additional","affiliation":[{"name":"Shire Human Genetic Therapies, Inc., Cambridge, Massachusetts (a Takeda company)"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"John P","family":"Bilezikian","sequence":"additional","affiliation":[{"name":"Columbia University College of Physicians and Surgeons, New York, New York"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"80","published-online":{"date-parts":[[2020,8,1]]},"reference":[{"key":"2021122106021074700_CIT0001","doi-asserted-by":"crossref","first-page":"319","DOI":"10.1007\/978-88-470-5376-2_30","article-title":"Treatment of hypoparathyroidism with parathyroid hormone 1\u201334.","volume-title":"Hypoparathyroidism","author":"Winer","year":"2015"},{"key":"2021122106021074700_CIT0002","doi-asserted-by":"crossref","first-page":"172","DOI":"10.3389\/fendo.2016.00172","article-title":"Review of hypoparathyroidism","volume":"7","author":"Abate","year":"2017","journal-title":"Front Endocrinol (Lausanne)."},{"issue":"3","key":"2021122106021074700_CIT0003","doi-asserted-by":"crossref","first-page":"478","DOI":"10.1002\/jbmr.3329","article-title":"A population-based study of the epidemiology of chronic hypoparathyroidism","volume":"33","author":"Vadiveloo","year":"2018","journal-title":"J Bone Miner Res."},{"issue":"8","key":"2021122106021074700_CIT0004","doi-asserted-by":"crossref","first-page":"3045","DOI":"10.1210\/jc.2016-1477","article-title":"Epidemiology and health-related quality of life in hypoparathyroidism in Norway","volume":"101","author":"Astor","year":"2016","journal-title":"J Clin Endocrinol Metab."},{"issue":"11","key":"2021122106021074700_CIT0005","doi-asserted-by":"crossref","first-page":"2504","DOI":"10.1002\/jbmr.2273","article-title":"Postsurgical hypoparathyroidism\u2013risk of fractures, psychiatric diseases, cancer, cataract, and infections","volume":"29","author":"Underbjerg","year":"2014","journal-title":"J Bone Miner Res."},{"issue":"9","key":"2021122106021074700_CIT0006","doi-asserted-by":"crossref","first-page":"1738","DOI":"10.1002\/jbmr.2501","article-title":"The epidemiology of nonsurgical hypoparathyroidism in Denmark: a nationwide case finding study","volume":"30","author":"Underbjerg","year":"2015","journal-title":"J Bone Miner Res."},{"issue":"25","key":"2021122106021074700_CIT0007","doi-asserted-by":"crossref","first-page":"1863","DOI":"10.1056\/NEJM200012213432508","article-title":"Hyperparathyroid and hypoparathyroid disorders.","volume":"343","author":"Marx","year":"2000","journal-title":"N Engl J Med."},{"issue":"1","key":"2021122106021074700_CIT0008","doi-asserted-by":"crossref","first-page":"202","DOI":"10.1002\/1097-0142(20000701)89:1<202::AID-CNCR27>3.0.CO;2-A","article-title":"Initial results from a prospective cohort study of 5583 cases of thyroid carcinoma treated in the United States during 1996. U.S. and German Thyroid Cancer Study Group. An American College of Surgeons Commission on Cancer Patient Care Evaluation study","volume":"89","author":"Hundahl","year":"2000","journal-title":"Cancer."},{"issue":"12","key":"2021122106021074700_CIT0009","doi-asserted-by":"crossref","first-page":"2570","DOI":"10.1002\/jbmr.2004","article-title":"Prevalence and incidence of hypoparathyroidism in the United States using a large claims database","volume":"28","author":"Powers","year":"2013","journal-title":"J Bone Miner Res."},{"issue":"10","key":"2021122106021074700_CIT0010","doi-asserted-by":"crossref","first-page":"2317","DOI":"10.1002\/jbmr.483","article-title":"Hypoparathyroidism in the adult: Epidemiology, diagnosis, pathophysiology, target-organ involvement, treatment, and challenges for future research","volume":"26","author":"Bilezikian","year":"2011","journal-title":"J Bone Miner Res."},{"issue":"12","key":"2021122106021074700_CIT0011","doi-asserted-by":"crossref","first-page":"4507","DOI":"10.1210\/jc.2012-1808","article-title":"Long-term follow-up of patients with hypoparathyroidism","volume":"97","author":"Mitchell","year":"2012","journal-title":"J Clin Endocrinol Metab."},{"issue":"22","key":"2021122106021074700_CIT0012","doi-asserted-by":"crossref","first-page":"1241","DOI":"10.1056\/NEJM197806012982206","article-title":"Hypercalcemia and increases in serum hormone value during prolonged administration of 1alpha,25-dihydroxyvitamin D","volume":"298","author":"Bell","year":"1978","journal-title":"N Engl J Med."},{"issue":"6053","key":"2021122106021074700_CIT0013","doi-asserted-by":"crossref","first-page":"78","DOI":"10.1136\/bmj.1.6053.78","article-title":"Rate of reversal of hypercalcaemia and hypercalciuria induced by vitamin D and its 1alpha-hydroxylated derivatives","volume":"1","author":"Kanis","year":"1977","journal-title":"Br Med J."},{"issue":"11","key":"2021122106021074700_CIT0014","doi-asserted-by":"crossref","first-page":"2277","DOI":"10.1002\/jbmr.1979","article-title":"Cardiovascular and renal complications to postsurgical hypoparathyroidism: a Danish nationwide controlled historic follow-up study","volume":"28","author":"Underbjerg","year":"2013","journal-title":"J Bone Miner Res."},{"issue":"9","key":"2021122106021074700_CIT0015","doi-asserted-by":"crossref","first-page":"3307","DOI":"10.1210\/jc.2008-1216","article-title":"Hypoparathyroidism: is it time for replacement therapy?","volume":"93","author":"Horwitz","year":"2008","journal-title":"J Clin Endocrinol Metab."},{"issue":"2","key":"2021122106021074700_CIT0016","doi-asserted-by":"crossref","first-page":"G1","DOI":"10.1530\/EJE-15-0628","article-title":"Clinical Guideline: treatment of chronic hypoparathyroidism in adults","volume":"173","author":"Bollerslev","year":"2015","journal-title":"Eur J Endocrinol."},{"issue":"4","key":"2021122106021074700_CIT0017","doi-asserted-by":"crossref","first-page":"275","DOI":"10.1016\/S2213-8587(13)70106-2","article-title":"Efficacy and safety of recombinant human parathyroid hormone (1\u201384) in hypoparathyroidism (REPLACE): a double-blind, placebo-controlled, randomised, phase 3 study","volume":"1","author":"Mannstadt","year":"2013","journal-title":"Lancet Diabetes Endocrinol."},{"key":"2021122106021074700_CIT0018","article-title":"Five-year efficacy and safety of recombinant human parathyroid hormone 1\u201384 (rhPTH[1\u201384]) for the treatment of adults with chronic hypoparathyroidism: analysis from the open-label RACE study","volume-title":"Annual Meeting of the Endocrine Society","author":"Shoback","year":"2018"},{"key":"2021122106021074700_CIT0019","doi-asserted-by":"crossref","DOI":"10.1530\/endoabs.56.GP177","article-title":"Maintenance of key biochemical parameters with recombinant human parathyroid hormone (1\u201384) in patients with hypoparathyroidism: an analysis of a long-term, open-label, single-centre study","volume-title":"European Congress of Endocrinology","author":"Krasner","year":"2018"},{"key":"2021122106021074700_CIT0020","doi-asserted-by":"crossref","DOI":"10.1210\/jc.2019-00893","article-title":"Therapy of hypoparathyroidism with rhPTH(1\u201384): a prospective eight year investigation of efficacy and safety","author":"Tay","year":"2019","journal-title":"J Clin Endocrinol Metab."},{"issue":"1","key":"2021122106021074700_CIT0021","doi-asserted-by":"crossref","first-page":"51","DOI":"10.1186\/s12893-016-0165-y","article-title":"Living-donor parathyroid allotransplantation for therapy-refractory postsurgical persistent hypoparathyroidism in a nontransplant recipient \u2013 three year results: a case report","volume":"16","author":"Agha","year":"2016","journal-title":"BMC Surg."},{"issue":"9","key":"2021122106021074700_CIT0022","doi-asserted-by":"crossref","first-page":"604","DOI":"10.7326\/0003-4819-150-9-200905050-00006","article-title":"A new equation to estimate glomerular filtration rate","volume":"150","author":"Levey","year":"2009","journal-title":"Ann Intern Med."},{"issue":"3","key":"2021122106021074700_CIT0023","doi-asserted-by":"crossref","first-page":"749","DOI":"10.1172\/JCI115947","article-title":"On the mechanism of parathyroid hormone stimulation of calcium uptake by mouse distal convoluted tubule cells","volume":"90","author":"Gesek","year":"1992","journal-title":"J Clin Invest."},{"issue":"5","key":"2021122106021074700_CIT0024","doi-asserted-by":"crossref","first-page":"760","DOI":"10.1038\/ki.1987.272","article-title":"Calcium-regulating hormones and the kidney","volume":"32","author":"Kurokawa","year":"1987","journal-title":"Kidney Int."},{"issue":"1","key":"2021122106021074700_CIT0025","doi-asserted-by":"crossref","first-page":"273","DOI":"10.1007\/s12020-016-1141-0","article-title":"Effects of parathyroid hormone rhPTH(1-84) on phosphate homeostasis and vitamin D metabolism in hypoparathyroidism: REPLACE phase 3 study","volume":"55","author":"Clarke","year":"2017","journal-title":"Endocrine."},{"issue":"1","key":"2021122106021074700_CIT0026","doi-asserted-by":"crossref","first-page":"137","DOI":"10.1210\/jc.2012-2984","article-title":"Therapy of hypoparathyroidism with PTH(1\u201384): a prospective four-year investigation of efficacy and safety","volume":"98","author":"Cusano","year":"2013","journal-title":"J Clin Endocrinol Metab."},{"issue":"7","key":"2021122106021074700_CIT0027","doi-asserted-by":"crossref","first-page":"2742","DOI":"10.1210\/jc.2015-4135","article-title":"Therapy of hypoparathyroidism with PTH(1-84): a prospective six-year investigation of efficacy and safety","volume":"101","author":"Rubin","year":"2016","journal-title":"J Clin Endocrinol Metab."},{"issue":"5","key":"2021122106021074700_CIT0028","doi-asserted-by":"crossref","first-page":"822","DOI":"10.1002\/jbmr.3368","article-title":"Long-term complications in patients with hypoparathyroidism evaluated by biochemical findings: a case-control study","volume":"33","author":"Underbjerg","year":"2018","journal-title":"J Bone Miner Res."},{"issue":"9","key":"2021122106021074700_CIT0029","doi-asserted-by":"crossref","first-page":"1125","DOI":"10.1592\/phco.28.9.1125","article-title":"Comparison of dosing recommendations for antimicrobial drugs based on two methods for assessing kidney function: Cockcroft-Gault and modification of diet in renal disease","volume":"28","author":"Golik","year":"2008","journal-title":"Pharmacotherapy."}],"container-title":["The Journal of Clinical Endocrinology &amp; Metabolism"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/academic.oup.com\/jcem\/advance-article-pdf\/doi\/10.1210\/clinem\/dgaa490\/33557364\/dgaa490.pdf","content-type":"application\/pdf","content-version":"am","intended-application":"syndication"},{"URL":"https:\/\/academic.oup.com\/jcem\/article-pdf\/105\/10\/e3557\/41828248\/dgaa490.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"https:\/\/academic.oup.com\/jcem\/article-pdf\/105\/10\/e3557\/41828248\/dgaa490.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2021,12,21]],"date-time":"2021-12-21T06:02:42Z","timestamp":1640066562000},"score":1,"resource":{"primary":{"URL":"https:\/\/academic.oup.com\/jcem\/article\/105\/10\/e3557\/5879689"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2020,8,1]]},"references-count":29,"journal-issue":{"issue":"10","published-online":{"date-parts":[[2020,8,1]]},"published-print":{"date-parts":[[2020,10,1]]}},"URL":"https:\/\/doi.org\/10.1210\/clinem\/dgaa490","relation":{},"ISSN":["0021-972X","1945-7197"],"issn-type":[{"value":"0021-972X","type":"print"},{"value":"1945-7197","type":"electronic"}],"subject":[],"published-other":{"date-parts":[[2020,10]]},"published":{"date-parts":[[2020,8,1]]}}}